| Features: |
| Erastin is often referred to as a "metabolic inhibitor" or a "ferroptosis inducer", rather than a traditional chemotherapy agent. Erastin is primarily available as a research chemical—it's not an approved therapeutic for clinical use. Pathways: -Erastin inhibits system xCT, thereby reducing cystine uptake. This leads to decreased intracellular cysteine, a precursor for GSH. As a consequence, the cell’s glutathione levels drop, compromising its ability to neutralize reactive oxygen species (ROS). -Glutathione (GSH) Depletion and Increased Oxidative Stress -Voltage-Dependent Anion Channels (VDACs): Altering VDAC function can affect mitochondrial metabolism, leading to changes in energy production and further enhancing oxidative stress. |
| Source: |
| Type: measure |
| TBARS (Thiobarbituric Acid Reactive Substances) is a measure of lipid peroxidation, which is the oxidative degradation of lipids. Lipid peroxidation is a process in which free radicals attack lipids containing carbon-carbon double bond(s), especially polyunsaturated fatty acids (PUFAs), leading to cell damage. Research has shown that TBARS levels are often elevated in cancer patients. This is because cancer cells have higher levels of reactive oxygen species (ROS) than normal cells, which can lead to increased lipid peroxidation. |
| 727- | Bor, | RSL3, | erastin, | Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy |
| - | in-vitro, | Liver, | HepG2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:241 Target#:862 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid